PULMONARY SURFACTANT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Pulmonary Surfactant Market, By Type (Synthetic Pulmonary Surfactant, Animal Derived Surfactant), By Drug Type (Poractant alfa, Lucinactant, Calfactant), By Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)), By Route of Administration (Intratracheal, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In: 27 Mar, 2026
Code: CMI5324
Page number: 168
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026 - 2033

Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It’s major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it’s major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves

bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant.

Market Dynamics

Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019.

Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.

Key features of the study

This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global pulmonary surfactant market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant

Market Segmentation

By Type
- Synthetic Pulmonary Surfactant
- Animal Derived Surfactant
By Drug Type
- Poractant alfa
- Lucinactant
- Calfactant
By Indications
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Obstructive lung Diseases
- Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
By Route of Administration
- Intratracheal
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Boehinger Ingelheim
- AbbVie Inc
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima (Noargen)
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Type
  - Market Snapshot, By Drug Type
  - Market Snapshot, By Indications
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Industry Trend
- New Product Approvals/Launch
- Merger and Acquisitions
- PEST Analysis
Global Pulmonary Surfactant Market, By Type, 2026 – 2033, (USD Million)
- Overview
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Synthetic Pulmonary Surfactant
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Animal Derived Surfactant
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Global Pulmonary Surfactant Market, By Drug Type, 2026 – 2033, (USD Million)
- Overview
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Poractant alfa
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Lucinactant
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Calfactant
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Global Pulmonary Surfactant Market, By Indications, 2026 – 2033, (USD Million)
- Overview
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Respiratory Distress Syndrome (RDS)
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Respiratory Infections
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Obstructive lung Diseases
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Global Pulmonary Surfactant Market, By Route of Administration, 2026 – 2033, (USD Million)
- Overview
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Intratracheal
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Injectable
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Global Pulmonary Surfactant Market, By Distribution Channel, 2026 – 2033, (USD Million)
- Overview
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Hospital Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Global Pulmonary Surfactant Market, By Region, 2026 – 2033, (USD Million)
- Introduction
  - Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, For Regions, 2021-2033
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - UK
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Company Profile
  - Boehringer Ingelheim
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - AbbVie Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Chiesi Farmaceutici
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - ONY Biotech Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Lyomark Pharma
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Abbott
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Aviva Systems Biology Corporation
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Windtree Therapeutics, Inc
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Tekzima (Noargen)
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Biomatik
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Nanjing Norris Pharm Technology
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Reddot Biotech
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
- Analyst Views
Section
- References
- Research Methodology
- About Us

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now